Baron B M, Dudley M W, McCarty D R, Miller F P, Reynolds I J, Schmidt C J
Merrell Dow Research Institute, Cincinnati, Ohio.
J Pharmacol Exp Ther. 1989 Jul;250(1):162-9.
Guanine nucleotides were shown to alter N-methyl-d-aspartate (NMDA) receptor-effector coupling by competitive antagonism at the glutamate binding site, rather than via interaction with an intracellularly located GTP-binding protein. Thus, in contrast to known G-protein linked receptors, micromolar concentrations of guanine nucleotides and their analogs decreased both agonist [( 3H]glutamate) and antagonist [( 3H]-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid binding to the NMDA receptor complex. The most potent compound, the GDP analog guanosine-5'-O-(2-thiodiphosphate) (GDP beta S), was studied in detail. GDP beta S exhibited almost 200-fold selectivity for the glutamate recognition site vs. the strychnine-insensitive glycine binding site. IC50 values were 2.7 +/- 1.4 and 484 +/- 97 microM, respectively. GDP beta S also inhibited N-[1-(2-thienyl)cyclohexyl-3H]piperidine binding (IC50 was 28.0 +/- 3.7 microM) in an NMDA-reversible fashion. [3H]-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid saturation binding studies revealed an increase in Kd from 263 +/- 49 (control) to 552 +/- 134 nM (8 microM GDP beta S) without any change in maximum binding (4.94 +/- 0.34 and 5.19 +/- 0.58 pmol/mg of protein, respectively). GDP beta S was also a competitive inhibitor of the following NMDA-stimulated responses: elevation of cyclic GMP in neonatal rat cerebellar slices, release of preloaded [3H]norepinephrine from superfused rat hippocampal slices and elevation of cytosolic calcium concentration in fura-2-loaded cultured rat forebrain neurons. IC50 values were 78.4, 53.4 and 1.6 microM, respectively. Finally, GDP beta S resembled known NMDA receptor antagonists in its ability to block NMDA receptor-induced seizures after i.c.v. administration.(ABSTRACT TRUNCATED AT 250 WORDS)
鸟嘌呤核苷酸被证明是通过在谷氨酸结合位点的竞争性拮抗作用来改变N-甲基-D-天冬氨酸(NMDA)受体与效应器的偶联,而不是通过与细胞内定位的GTP结合蛋白相互作用。因此,与已知的G蛋白偶联受体不同,微摩尔浓度的鸟嘌呤核苷酸及其类似物会降低激动剂[(3H)谷氨酸]和拮抗剂[(3H)-3-(2-羧基哌嗪-4-基)-丙基-1-膦酸]与NMDA受体复合物的结合。对最有效的化合物,即GDP类似物鸟苷-5'-O-(2-硫代二磷酸)(GDPβS)进行了详细研究。GDPβS对谷氨酸识别位点的选择性比对士的宁不敏感的甘氨酸结合位点高近200倍。IC50值分别为2.7±1.4和484±97μM。GDPβS还以NMDA可逆的方式抑制N-[1-(2-噻吩基)环己基-3H]哌啶结合(IC50为28.0±3.7μM)。[3H]-3-(2-羧基哌嗪-4-基)-丙基-1-膦酸饱和结合研究表明,Kd从263±49(对照)增加到552±134 nM(8μM GDPβS),最大结合量没有任何变化(分别为4.94±0.34和5.19±0.58 pmol/mg蛋白质)。GDPβS还是以下NMDA刺激反应的竞争性抑制剂:新生大鼠小脑切片中环状GMP的升高、从灌注的大鼠海马切片中释放预先加载的[3H]去甲肾上腺素以及fura-2负载的培养大鼠前脑神经元中细胞溶质钙浓度的升高。IC50值分别为78.4、53.4和1.6μM。最后,GDPβS在脑室内给药后阻断NMDA受体诱发癫痫发作的能力与已知的NMDA受体拮抗剂相似。(摘要截短于250字)